IXHL’s 3Q26 results and subsequent clinical update move IHL-42X from Phase 2 validation toward dose-optimization execution ahead of Phase 3. The key change is the start of DReAMzz, a crossover study designed to refine the dronabinol/acetazolamide ratio, incorporate FDA feedback, and strengthen the Phase 3 protocol before larger late-stage capital is committed. For investors, the next several quarters should be judged less on quarterly P&L and more on site activation, dosing, recruitment cadence, and whether DReAMzz supports a more defined registrational path for an oral OSA therapy.
